EUVIMEDEUVIMED entdecken
Fallbericht

Recurrent Reactions to Enzyme Replacement Therapy in Infantile‐Onset Pompe Disease: A Case of Immunologic Barriers to Drug Tolerance

Nikhil A Crain iD, Priya Chopra iD, Michael Q Sanderson, Janet A Thomas iD, Ankit K Desai, Priya S Kishnani iD, Laura Ann Wang

American Journal of Medical Genetics Part A · 30.10.2026

DOI: 10.1002/ajmg.a.70349 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Medical Genetics Part A, online erschienen am 30.10.2026. Verfasst von Nikhil A Crain und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infantile‐Onset Pompe Disease (IOPD) is a rapidly progressive lysosomal disorder caused by acid alpha‐glucosidase (GAA) deficiency with universal mortality if untreated. Enzyme replacement therapy (ERT) with recombinant human acid alpha‐glucosidase (rhGAA) is lifesaving; however, the development of IgG anti‐drug antibodies (ADAs), especially in cross‐reactive immunologic material (CRIM)‐negative patients, can adversely affect ERT efficacy and safety, including an increased risk of infusion‐associated reactions (IARs). We describe a patient with CRIM‐negative IOPD who developed clinical decline and severe IARs associated with high IgG ADA titers that warranted several rounds of immune tolerance induction (ITI) and a desensitization protocol. Following a clinical diagnosis, ERT with alglucosidase alfa (40 mg/kg/week) with concomitant prophylactic ITI consisting of a short course of rituximab, methotrexate, and intravenous immunoglobulin were initiated at age 6.25 months. Despite early clinical improvement, ADA titers first rose to 12,800 at 12 months and rose to 25,600 at 17 months, prompting a second ITI regimen consisting of rituximab, methotrexate, intravenous immunoglobulin, and bortezomib to target plasma cells. Between ages 34 and 40 months (28–34 months on ERT), she developed recurrent infusion reactions resembling anaphylaxis to previously tolerated ERT with peak ADA titers of 25,600 at 41 months. An additional bortezomib‐based ITI protocol with desensitization was administered due to persistence of high‐sustained antibody titers (HSATs). Subsequently, the patient was able to tolerate ERT, and she has since continued clinical improvement with declining ADA titers to 1600 at 52 months. Immune modulation is now being tapered. This case highlights the immunological challenges of ERT in CRIM‐negative IOPD patients and how multidisciplinary immunosuppression strategies can maintain lifesaving therapies.

Schlagwörter

Stichwörter der Autor:innen

Pompe diseasebortezomibenzyme replacement therapyhigh‐sustained antibody titersimmune tolerance induction

Autor:innen und Institutionen

  • Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Pediatrics, Section of Allergy & Immunology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Pediatrics, Sheridan Memorial Hospital, Sheridan, Wyoming, USA.
  • Department of Pediatrics, Section of Clinical Genetics and Metabolism, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Pediatrics, Division of Medical Genetics, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Nikhil A Crain, Priya Chopra, Janet A Thomas, Priya S Kishnani

Zitieren

APA

Crain, N. A., Chopra, P., Sanderson, M. Q., Thomas, J. A., Desai, A. K., Kishnani, P. S., & Wang, L. A. (2026). Recurrent Reactions to Enzyme Replacement Therapy in Infantile‐Onset Pompe Disease: A Case of Immunologic Barriers to Drug Tolerance. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.70349

Vancouver

Crain NA, Chopra P, Sanderson MQ, Thomas JA, Desai AK, Kishnani PS, et al. Recurrent Reactions to Enzyme Replacement Therapy in Infantile‐Onset Pompe Disease: A Case of Immunologic Barriers to Drug Tolerance. American Journal of Medical Genetics Part A. 2026. doi:10.1002/ajmg.a.70349

BibTeX
@article{Crain2026,
  author = {Crain, Nikhil A and Chopra, Priya and Sanderson, Michael Q and Thomas, Janet A and Desai, Ankit K and Kishnani, Priya S and Wang, Laura Ann},
  title = {Recurrent Reactions to Enzyme Replacement Therapy in Infantile‐Onset Pompe Disease: A Case of Immunologic Barriers to Drug Tolerance},
  journal = {American Journal of Medical Genetics Part A},
  year = {2026},
  doi = {10.1002/ajmg.a.70349}
}
Kostenlos starten →